Shares of pharma major Lupin will remain in focus, as the company on Monday said it has launched its testosterone topical solution in the United States. The company has launched Testosterone Topical Solution, 30 mg per actuation, in the US after receiving approval from the United States Food and Drug Administration, Lupin said. The company’s product is the generic version of Eli Lilly and the company’s Axiron topical solution, 30 mg per actuation, it added.
Previous Story Nikkei leads Asia higher; European bourses seen opening up
MORE FROM BUSINESSLINE
Getting recommendations just for you...
- Comments will be moderated by The Hindu Business Line editorial team.
- Comments that are abusive, personal, incendiary or irrelevant cannot be published.
- Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
- We may remove hyperlinks within comments.
- Please use a genuine email ID and provide your name, to avoid rejection.